Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Vinati Organics Limited, established in Mumbai, India in 1989, operates as a specialty chemical enterprise specializing in the production and global distribution of organic intermediaries and monomers. While primarily serving the Indian market, the company also exports its diverse product range to key international regions including the United States, Europe, and various parts of Asia. Its extensive portfolio features a variety of specialty monomers, such as 2-acrylamido-2-methylpropane sulphonic acid (2-AMPS) and its sodium salt, alongside N-tertiary butyl acrylamide (NTBA) and N-tertiary octyl acrylamide (NTOA). The company is also a significant producer of aromatic compounds. These include isobutyl benzene, a critical precursor for manufacturing ibuprofen, an anti-inflammatory analgesic drug; normal butyl benzene, utilized in the synthesis of numerous chemical intermediates; and hexenes, valued for applications like low-boiling point solvents, thinners, extraction agents, tire retreading, as octane boosters for gasoline, and in C5/C6 aliphatic petroleum. Butyl phenols are also part of this segment. Further expanding its chemical offerings, Vinati Organics provides methyl-4-tert butyl benzoate and para tertiary butyl benzoic acid. It manufactures isobutylene, a branched olefin; methanol, which functions as a chemical intermediate; and high-purity methyl tertiary butyl ether (MTBE), widely used as a solvent in organic and pharmaceutical synthesis, as well as in Grignard's reagent production. Tertiary-butylamine is another specialized chemical produced. Additionally, the firm develops polymers tailored for diverse industrial sectors, including construction, ceramics, oil drilling, mining, leather processing, and paper manufacturing.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, r
Target Price
The average target price of VINATIORGA.NS is 1854 and suggests 40.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendatio